Targeting Biomarker-Defined Cancers
Merrimack has a proven history of successfully discovering and developing novel therapeutics that have helped to shape new treatment strategies for patients. That includes the successful development and approval for ONIVYDE®1 (irinotecan liposome injection) to treat patients with advanced pancreatic cancer who have previously been treated with gemcitabine-based chemotherapy.
Today, that journey continues. Merrimack is developing a new generation of solutions for cancer through a focused pipeline of precise, targeted therapies. A cornerstone of our development strategy is to establish efficacy and value through studies in biomarker-enriched patient populations.
1ONIVYDE® was acquired by Ipsen S.A. in April 2017.
Focused Research Strategy
We are taking a systematic approach to our preclinical development work. These and other innovative programs utilizing our biomarker-driven approach will provide future opportunities to enter the clinic to help patients in need.
Published research & presentations
Sawyer et al, AACR, 2019
Ghassemifar et al, AACR, 2019
Sampson et al, AACR, 2019